|
DE3583799D1
(de)
*
|
1985-01-11 |
1991-09-19 |
Abbott Lab Ltd |
Feste zubereitung mit langsamer freisetzung.
|
|
EP0250572A1
(en)
*
|
1986-01-03 |
1988-01-07 |
The University Of Melbourne |
Gastro-oesophageal reflux composition
|
|
CA1302659C
(en)
*
|
1986-10-24 |
1992-06-09 |
Hans-Peter K. Gribi |
Dental impression material
|
|
EP0275336A1
(de)
*
|
1987-01-20 |
1988-07-27 |
Knoll Ag |
Arzneimittelzubereitung mit protahierender Wirkung
|
|
US5064736A
(en)
*
|
1988-03-23 |
1991-11-12 |
Olin Corporation |
Electrostatic method for multicolor imaging from a single toner bath
|
|
DE4002281A1
(de)
*
|
1990-01-26 |
1991-08-01 |
Lohmann Therapie Syst Lts |
Transdermales therapeutisches system mit dem wirkstoff tulobuterol
|
|
NL9002008A
(nl)
|
1990-09-12 |
1992-04-01 |
Stichting Centr Diergeneeskund |
Recombinant dna en rna en daarvan afgeleide produkten.
|
|
FR2676364B1
(fr)
*
|
1991-05-17 |
1993-09-10 |
Lafon Labor |
Composition pharmaceutique a base de derives d'aminobutanone.
|
|
US5368862A
(en)
*
|
1991-12-18 |
1994-11-29 |
Merck & Co., Inc. |
Sustained release tablets containing alginate
|
|
US5411746A
(en)
*
|
1993-02-24 |
1995-05-02 |
Warner-Jenkinson Company, Inc. |
Dye compositions and methods for film coating tablets and the like
|
|
US5670169A
(en)
*
|
1993-12-20 |
1997-09-23 |
E.R. Squibb & Sons, Inc. |
Wound hydrating gel with novel preservative system and low cytotoxicity
|
|
US6692766B1
(en)
*
|
1994-06-15 |
2004-02-17 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Controlled release oral drug delivery system
|
|
DE4443358A1
(de)
*
|
1994-12-06 |
1996-06-13 |
Basf Ag |
Depot-Arzneimittel
|
|
US5879712A
(en)
*
|
1995-06-07 |
1999-03-09 |
Sri International |
Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
|
|
US5811126A
(en)
*
|
1995-10-02 |
1998-09-22 |
Euro-Celtique, S.A. |
Controlled release matrix for pharmaceuticals
|
|
US5705190A
(en)
*
|
1995-12-19 |
1998-01-06 |
Abbott Laboratories |
Controlled release formulation for poorly soluble basic drugs
|
|
US6010718A
(en)
*
|
1997-04-11 |
2000-01-04 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
|
US20050064033A1
(en)
*
|
1997-04-11 |
2005-03-24 |
Notario Gerard F. |
Extended release formulations of erythromycin derivatives
|
|
US6551616B1
(en)
*
|
1997-04-11 |
2003-04-22 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
|
SK282427B6
(sk)
*
|
1997-06-11 |
2002-01-07 |
Abbott Laboratories |
Pevná farmaceutická kompozícia s riadeným uvoľňovaním
|
|
IN186245B
(es)
|
1997-09-19 |
2001-07-14 |
Ranbaxy Lab Ltd |
|
|
US7022683B1
(en)
*
|
1998-05-13 |
2006-04-04 |
Carrington Laboratories, Inc. |
Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
|
|
BG65116B1
(bg)
*
|
2000-01-06 |
2007-03-30 |
Abbott Laboratories |
Лекарствена форма с контролирано освобождаване наслабо разтворими основни лекарствени средства
|
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
|
US6565882B2
(en)
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
|
HRP20020709A2
(en)
*
|
2000-02-29 |
2004-12-31 |
Teva Pharma |
Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
|
|
US6541014B2
(en)
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
|
US7494669B2
(en)
*
|
2001-02-28 |
2009-02-24 |
Carrington Laboratories, Inc. |
Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
|
|
US6777000B2
(en)
*
|
2001-02-28 |
2004-08-17 |
Carrington Laboratories, Inc. |
In-situ gel formation of pectin
|
|
RU2200002C1
(ru)
*
|
2001-07-30 |
2003-03-10 |
Акционерное Курганское общество медицинских препаратов и изделий "Синтез" |
Твердая фармацевтическая композиция и способ ее получения
|
|
US6642276B2
(en)
*
|
2001-10-01 |
2003-11-04 |
M/S Ind-Swift Limited |
Controlled release macrolide pharmaceutical formulations
|
|
WO2003037304A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Wockhardt Limited |
Controlled release compositions for macrolide antimicrobial agents
|
|
US6602911B2
(en)
|
2001-11-05 |
2003-08-05 |
Cypress Bioscience, Inc. |
Methods of treating fibromyalgia
|
|
WO2003105810A1
(en)
*
|
2002-06-14 |
2003-12-24 |
Andrx Corporation |
Pharmaceutical compositions for drugs having ph-dependentsolubility
|
|
SI21300A
(sl)
*
|
2002-10-08 |
2004-04-30 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Farmacevtske formulacije z alginati
|
|
US20100092562A1
(en)
*
|
2002-11-26 |
2010-04-15 |
Hollenbeck R Gary |
Sustained-release drug delivery compositions and methods
|
|
GB0230034D0
(en)
*
|
2002-12-23 |
2003-01-29 |
Biochemie Gmbh |
Organic compounds
|
|
US7063862B2
(en)
*
|
2003-06-03 |
2006-06-20 |
Biokey, Inc. |
Pharmaceutical composition and method for treating
|
|
CA2529746C
(en)
*
|
2003-06-16 |
2010-08-03 |
Andrx Pharmaceuticals, Llc |
Oral extended-release composition
|
|
US20050053658A1
(en)
*
|
2003-09-09 |
2005-03-10 |
Venkatesh Gopi M. |
Extended release systems for macrolide antibiotics
|
|
JP2006528189A
(ja)
|
2003-07-21 |
2006-12-14 |
アドバンシス ファーマスーティカル コーポレイション |
抗生物質産物、その使用法および製剤
|
|
CA2533358C
(en)
|
2003-07-21 |
2014-03-11 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
|
US8313775B2
(en)
|
2003-07-21 |
2012-11-20 |
Shionogi Inc. |
Antibiotic product, use and formulation thereof
|
|
JP2007502296A
(ja)
|
2003-08-11 |
2007-02-08 |
アドバンシス ファーマスーティカル コーポレイション |
ロバストペレット
|
|
WO2005016278A2
(en)
|
2003-08-12 |
2005-02-24 |
Advancis Pharmaceuticals Corporation |
Antibiotic product, use and formulation thereof
|
|
EP1658034A4
(en)
|
2003-08-29 |
2011-06-22 |
Middlebrook Pharmaceuticals Inc |
ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
|
|
US8460710B2
(en)
|
2003-09-15 |
2013-06-11 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
|
US8168228B2
(en)
*
|
2003-10-17 |
2012-05-01 |
Sandoz Ag |
Antibiotic clarithromycin micropellet compositions
|
|
US20050084540A1
(en)
*
|
2003-10-17 |
2005-04-21 |
Indranil Nandi |
Taste masking antibiotic composition
|
|
US20050101547A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Sadatrezaei Mohsen |
Stabilized azithromycin composition
|
|
US7943585B2
(en)
|
2003-12-22 |
2011-05-17 |
Sandoz, Inc. |
Extended release antibiotic composition
|
|
WO2005074598A2
(en)
|
2004-01-30 |
2005-08-18 |
Johns Hopkins University |
Nitroxyl progenitor compounds and methods of use
|
|
US20050260263A1
(en)
*
|
2004-05-18 |
2005-11-24 |
Panion & Bf Biotech Inc. |
Sustained release formulation for sparingly soluble main drugs
|
|
EP1765336A4
(en)
|
2004-06-25 |
2010-03-10 |
Univ Johns Hopkins |
ANGIOGENESIS INHIBITORS
|
|
CA2572292A1
(en)
|
2004-07-02 |
2006-02-09 |
Advancis Pharmaceutical Corporation |
Tablet for pulsed delivery
|
|
US20070020333A1
(en)
*
|
2005-07-20 |
2007-01-25 |
Chin-Chih Chiang |
Controlled release of hypnotic agents
|
|
CA2616366A1
(en)
|
2005-07-29 |
2007-02-08 |
Concert Pharmaceuticals Inc. |
Novel pharmaceutical compounds
|
|
WO2007016338A2
(en)
*
|
2005-07-29 |
2007-02-08 |
Goverment Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Use of chk2 kinase inhibitors for cancer treatment
|
|
US7994220B2
(en)
*
|
2005-09-28 |
2011-08-09 |
Cypress Bioscience, Inc. |
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
|
US20070128272A1
(en)
*
|
2005-12-07 |
2007-06-07 |
Zerbe Horst G |
Multi-vitamin and mineral supplement
|
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
|
US8778924B2
(en)
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
|
PL2489350T3
(pl)
*
|
2006-03-17 |
2014-08-29 |
Cardioxyl Pharmaceuticals Inc |
Pochodne N-hydroksylosulfonamidu jako nowe, fizjologicznie użyteczne donory nitroksylu
|
|
US8299052B2
(en)
*
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
|
CA2675755C
(en)
|
2007-01-19 |
2015-10-06 |
Xcovery, Inc. |
Pyridine and pyridazine derivatives as kinase inhibitors
|
|
SG10201602375PA
(en)
|
2007-09-26 |
2016-05-30 |
Univ Johns Hopkins |
N-Hydroxylsulfonamide Derivatives As New Physiologically Useful Nitroxyl Donors
|
|
BRPI0821454B8
(pt)
*
|
2007-12-28 |
2021-05-25 |
Acraf |
formulação farmacêutica, mistura de glicogênio, alginato e sais de metais alcalino terrosos, processos para a produção de um excipiente de liberação lenta, e de uma forma farmacêutica
|
|
WO2009137717A1
(en)
|
2008-05-07 |
2009-11-12 |
Cardioxyl Pharmaceuticals Inc. |
Novel nitroso compounds as nitroxyl donors and methods of use thereof
|
|
PL2303018T3
(pl)
|
2008-06-19 |
2016-06-30 |
Xcovery Holdings Inc |
Podstawione związki pirydazynokarboksyamidowe jako związki będące inhibitorami kinazy
|
|
US8729097B2
(en)
|
2008-10-06 |
2014-05-20 |
The Johns Hopkins University |
Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders
|
|
WO2011063339A1
(en)
*
|
2009-11-23 |
2011-05-26 |
Cardioxyl Pharmaceuticals, Inc. |
Nitroxyl donors for the treatment of pulmonary hypertension
|
|
EP2506711B1
(en)
|
2009-12-03 |
2019-04-03 |
OPKO Health, Inc. |
Hypersulfated disaccharide formulations
|
|
JP5826762B2
(ja)
|
2009-12-07 |
2015-12-02 |
ザ ジョンズ ホプキンス ユニバーシティ |
Ｎ−アシルオキシスルホンアミドおよびｎ−ヒドロキシ−ｎ−アシルスルホンアミド誘導体
|
|
IN2012DN05028A
(es)
|
2009-12-07 |
2015-10-23 |
Univ Johns Hopkins |
|
|
US20120082719A1
(en)
*
|
2010-10-05 |
2012-04-05 |
Sam Poon Ang |
Compositions For Treating Chronic Viral Infections
|
|
US20120082720A1
(en)
*
|
2010-10-05 |
2012-04-05 |
Sam Poon Ang |
Compositions For Treating Chronic Viral Infections
|
|
WO2012048259A2
(en)
|
2010-10-08 |
2012-04-12 |
Xcovery Holding Company, Llc |
Substituted pyridazine carboxamide compounds
|
|
CN104053647B
(zh)
|
2011-10-17 |
2018-06-01 |
约翰斯霍普金斯大学 |
作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物
|
|
EP2914579A1
(en)
|
2012-11-01 |
2015-09-09 |
The Johns Hopkins University |
Controlled hno release through intramolecular cyclization-elimination
|
|
PT2945621T
(pt)
|
2013-01-18 |
2019-01-21 |
Cardioxyl Pharmaceuticals Inc |
Composições farmacêuticas compreendendo dadores de nitroxilo
|
|
CA2908434C
(en)
|
2013-04-07 |
2021-12-28 |
The Broad Institute, Inc. |
Compositions and methods for personalized neoplasia vaccines
|
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
AU2014368898B2
(en)
|
2013-12-20 |
2020-06-11 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy with neoantigen vaccine
|
|
WO2015109210A1
(en)
|
2014-01-17 |
2015-07-23 |
Cardioxyl Pharmaceuticals, Inc. |
N-hydroxymethanesulfonamide nitroxyl donors
|
|
US9464061B2
(en)
|
2014-05-27 |
2016-10-11 |
The Johns Hopkins University |
N-hydroxylamino-barbituric acid derivatives
|
|
WO2015183838A1
(en)
|
2014-05-27 |
2015-12-03 |
The Johns Hopkins University |
N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
|
|
ES2749682T3
(es)
|
2014-05-27 |
2020-03-23 |
Cardioxyl Pharmaceuticals Inc |
Derivados de pirazolona como donadores de nitroxilo
|
|
EP3234193B1
(en)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
ES3049406T3
(en)
|
2014-12-19 |
2025-12-16 |
Broad Inst Inc |
Methods for profiling the t-cell-receptor repertoire
|
|
EP3237399B1
(en)
|
2014-12-23 |
2022-11-30 |
Avalo Therapeutics, Inc. |
Compounds, compositions and methods
|
|
IL294183B2
(en)
|
2015-05-20 |
2023-10-01 |
Dana Farber Cancer Inst Inc |
shared neoantigens
|
|
WO2016201146A1
(en)
|
2015-06-09 |
2016-12-15 |
Rexahn Pharmaceuticals, Inc. |
Fluorocyclopentenylcytosine uses and processes of preparation
|
|
KR101592144B1
(ko)
|
2015-06-19 |
2016-02-04 |
고려대학교 산학협력단 |
요오드 캡슐, 이의 제조방법 및 이를 포함하는 소금
|
|
US10383825B2
(en)
|
2015-08-13 |
2019-08-20 |
Temple University—Of the Commonwealth System of Higher Education |
Calcium alginate dosage formulations, and methods of making and using thereof
|
|
US9969698B2
(en)
|
2015-09-04 |
2018-05-15 |
Rexahn Pharmaceuticals, Inc. |
Quinoxalinyl-piperazinamide methods of use
|
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
|
US10738060B2
(en)
|
2016-10-03 |
2020-08-11 |
TLL Pharmaceutical, LLC |
JAK1 selective inhibitors and uses thereof
|
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
EP3788147A1
(en)
|
2018-05-04 |
2021-03-10 |
Tollys |
Tlr3 ligands that activate both epithelial and myeloid cells
|
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
WO2020215037A1
(en)
|
2019-04-18 |
2020-10-22 |
The Regents Of The University Of Michigan |
Combination with checkpoint inhibitors to treat cancer
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US20230203477A1
(en)
|
2020-05-26 |
2023-06-29 |
The Broad Institute, Inc. |
Nucleic acid artificial mini-proteome libraries
|
|
WO2021248093A1
(en)
|
2020-06-05 |
2021-12-09 |
Henry Ford Health System |
Daclatasvir for use in treating lung and prostate cancer
|
|
JP2024501995A
(ja)
|
2020-12-22 |
2024-01-17 |
メカニスティク・セラピューティクス・エルエルシー |
Ｅｇｆｒ及び／又はｐｉ３ｋ阻害剤としての置換アミノベンジルヘテロアリール化合物
|
|
WO2022189861A1
(en)
|
2021-03-08 |
2022-09-15 |
Tollys |
Carbohydrate conjugates of tlr3 ligands and uses thereof
|
|
EP4385510A4
(en)
|
2021-08-10 |
2025-08-20 |
Betta Pharmaceuticals Co Ltd |
USE OF ENSARTINIB OR A CORRESPONDING SALT IN THE TREATMENT OF A DISEASE CARRYING A MET EXON 14 SKIPPING MUTATION
|
|
EP4426829A1
(en)
|
2021-11-01 |
2024-09-11 |
Dana-Farber Cancer Institute, Inc. |
Biologically selected nucleic acid artificial mini-proteome libraries
|
|
WO2025043108A1
(en)
|
2023-08-23 |
2025-02-27 |
Bristol -Myers S Quibb Company |
Co-crystals of nitroxyl donating compounds
|
|
WO2025101914A1
(en)
|
2023-11-10 |
2025-05-15 |
Mekanistic Therapeutics Llc |
Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors having improved therapeutic index against solid tumors
|
|
WO2025126109A1
(en)
|
2023-12-15 |
2025-06-19 |
Ensem Therapeutics, Inc. |
Anilino-pyrazole derivatives, compositions and methods thereof
|